MedTrace Logo

AZAHAR Study To Describe Anifrolumab in a Real-World Setting

NCT06626945 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 152

Last updated 2025-06-24

No results posted yet for this study

Summary

AZAHAR is an observational retrospective and longitudinal study with adults patients with SLE who initiated treatment with anifrolumab from June 1, 2023 to May 31, 2024.

The overall objective is to describe the characteristics and clinical outcomes of patients with SLE that initiated anifrolumab during its first year of commercialization in Spain.

Conditions

  • Systemic Lupus Erythematosus (SLE)

Sponsors & Collaborators

Principal Investigators

  • Josefina Cortés-Hernández, MD, PhD · Unit of Lupus, VHIR-Hospital Universitary Vall d'Hebrón

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-03
Primary Completion
2025-06-05
Completion
2025-06-05

Countries

  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06626945 on ClinicalTrials.gov